Improvement after thalidomide and dexamethasone treatment for advanced cardiac amyloidosis - A case report

Circulation Journal

Volumn 71, Issue 11, 2007, Pages 1823-1825

  Jin, Sung Choi ^a   Eui, Nam Hwang ^a   Kim, Young Hoon ^a   Jung, Yunjin ^a   Kim, Hye Jeong ^a   Nam, Seung Hyun ^a   Park, Joong Il ^a  

^a Seoul Veterans Hospital   (South Korea)

Author keywords

Amyloidosis; Heart failure; Thalidomide

Indexed keywords

DEXAMETHASONE; THALIDOMIDE;

ADULT; ANAMNESIS; ANOREXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DIASTOLIC HEART FAILURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART AMYLOIDOSIS; HEART FUNCTION; HUMAN; MALE; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

AMYLOIDOSIS; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; THALIDOMIDE; TREATMENT OUTCOME;

EID: 36949031501     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1823     Document Type: Article

References (10)

1. Kristen AV, Meyer FJ, Perz JB, Schonland SO, Hundemer M, Hegenbart U, et al. Risk stratification in cardiac amyloidosis: Novel approaches. Transplantation 2005; 80: 151-155.
2. Falk RH. Diagnosis and management of the cardiac amyloisodes. Circulation 2005; 112: 2047-2060.
3. Talk RH, Comenzo RF, Skinner M. The systemic amyloidosis. N Engl J Med 1997; 337: 898-909.
4. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis. Blood 2005; 105: 2949-2951.
5. Kyle RA, Gertz MA, Greipp PR, Witzig TL, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: Colchicine alone. melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207.
6. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002; 117: 886-889.
7. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445.
8. Neil M, Simon GR. Cardiac amylodosis. Clin Med 2005; 5: 504-509.
9. Nils ON, Cathrine WK, Trygve H, Øystein AV, John P, Mons L, et al. The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis: One year follow-up. Eur J Heart Fail 2006; 8: 257-262.
10. Lars G, Thor U, Jan G F, Even H, Torstein G, Kjell B, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure results of a double-blind, placebo-controlled study. Circulation 2005; 112: 3408-3414.